CABOMETYX® (cabozantinib) in Renal Cell Carcinoma

This site is intended to provide healthcare professionals with information on CABOMETYX® and its therapeutic use in renal cell carcinoma (RCC).

Learn more
© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.se website. This website is intended for Sweden Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A SWEDEN HEALTHCARE PROFESSIONAL

I AM A EU HEALTHCARE PROFESSIONAL

I AM NOT A SWEDEN HEALTHCARE PROFESSIONAL